{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:50:46Z","timestamp":1793321446374,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973258"],"award-info":[{"award-number":["81973258"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202092"],"award-info":[{"award-number":["7202092"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L202044"],"award-info":[{"award-number":["L202044"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jconrel.2022.11.053","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T13:09:40Z","timestamp":1670418580000},"page":"423-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":200,"special_numbering":"C","title":["Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies"],"prefix":"10.1016","volume":"353","author":[{"given":"Ji","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianrong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7378","key":"10.1016\/j.jconrel.2022.11.053_bb0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2022.11.053_bb0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating next-generation dendritic cell vaccines into the current Cancer immunotherapy landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.11.053_bb0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm0598-594","article-title":"Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes","volume":"4","author":"L. Z","year":"1998","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.053_bb0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1158\/0008-5472.CAN-09-3276","article-title":"Dendritic cell-derived exosomes for cancer immunotherapy: what\u2019s next?","volume":"70","author":"Viaud","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.053_bb0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1172\/JCI81137","article-title":"Dendritic cell-derived exosomes for cancer therapy","volume":"126","author":"Pitt","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.053_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.053_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-5876-3-9","article-title":"A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer","volume":"3","author":"Morse","year":"2005","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.053_bb0040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1071008","article-title":"Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC","volume":"5","author":"Besse","year":"2016","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.053_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"6230","key":"10.1016\/j.jconrel.2022.11.053_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jconrel.2022.11.053_bb0055","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"issue":"7549","key":"10.1016\/j.jconrel.2022.11.053_bb0060","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.jconrel.2022.11.053_bb0065","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.jconrel.2022.11.053_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.053_bb0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2022.11.053_bb0080","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.4049\/jimmunol.1203082","article-title":"Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity","volume":"190","author":"Naslund","year":"2013","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.053_bb0085","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1807","article-title":"Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes","volume":"29","author":"Alvarez-Erviti","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"26","key":"10.1016\/j.jconrel.2022.11.053_bb0090","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1016\/j.biomaterials.2012.05.034","article-title":"A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma","volume":"33","author":"Tian","year":"2012","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.jconrel.2022.11.053_bb0095","first-page":"13","article-title":"Bioinspired exosome-mimetic Nanovesicles for targeted delivery of chemotherapeutics toMalignant tumors","volume":"7","author":"Su Chul Jang","year":"2013","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.053_bb0100","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1021\/acsnano.5b06939","article-title":"Blood exosomes endowed with magnetic and targeting properties for Cancer therapy","volume":"10","author":"Qi","year":"2016","journal-title":"ACS Nano"},{"issue":"Pt B","key":"10.1016\/j.jconrel.2022.11.053_bb0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","article-title":"Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells","volume":"220","author":"Saari","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.11.053_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jconrel.2017.08.009","article-title":"Lymph node targeting strategies to improve vaccination efficacy","volume":"267","author":"Jiang","year":"2017","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2022.11.053_bb0115","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","article-title":"Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma","volume":"9","author":"Guo","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2022.11.053_bb0120","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1021\/acs.nanolett.9b00030","article-title":"Targeted Codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced Cancer immunotherapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Nano Lett."},{"issue":"7","key":"10.1016\/j.jconrel.2022.11.053_bb0125","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.11.053_bb0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.11.053_bb0135","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1021\/acsnano.8b00558","article-title":"\u201cminimalist\u201d Nanovaccine constituted from near whole antigen for Cancer immunotherapy","volume":"12","author":"Wang","year":"2018","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.jconrel.2022.11.053_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle-enhanced radiotherapy to trigger robust Cancer immunotherapy","volume":"31","author":"Chen","year":"2019","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.053_bb0145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2013.08.021","article-title":"Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis","volume":"172","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.11.053_bb0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.11.053_bb0155","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/nn305466z","article-title":"pH-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides","volume":"7","author":"Wilson","year":"2013","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.jconrel.2022.11.053_bb0160","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7528","key":"10.1016\/j.jconrel.2022.11.053_bb0165","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2022.11.053_bb0170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.053_bb0175","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41467-017-01386-7","article-title":"Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy","volume":"8","author":"Zhu","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.11.053_bb0180","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.053_bb0185","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1021\/acs.bioconjchem.7b00761","article-title":"Subcutaneous Nanodisc vaccination with Neoantigens for combination Cancer immunotherapy","volume":"29","author":"Kuai","year":"2018","journal-title":"Bioconjug. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2022.11.053_bb0190","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1021\/acsnano.0c02765","article-title":"Co-delivery of peptide Neoantigens and stimulator of interferon genes agonists enhances response to Cancer vaccines","volume":"14","author":"Shae","year":"2020","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.053_bb0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat. Mater."},{"issue":"3","key":"10.1016\/j.jconrel.2022.11.053_bb0200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri3622","article-title":"Regulation of immune responses by extracellular vesicles","volume":"14","author":"Robbins","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"suppl_12","key":"10.1016\/j.jconrel.2022.11.053_bb0205","doi-asserted-by":"crossref","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"Sanchez-Paulete","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2022.11.053_bb0210","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 Cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"5480","key":"10.1016\/j.jconrel.2022.11.053_bb0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/252252a0","article-title":"Liposomes as immunological adjuvants","volume":"252","author":"Allison","year":"1974","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2022.11.053_bb0220","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/acs.molpharmaceut.1c00447","article-title":"Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines","volume":"18","author":"Chatzikleanthous","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.11.053_bb0225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front. Immunol."},{"issue":"Pt A","key":"10.1016\/j.jconrel.2022.11.053_bb0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2015.11.005","article-title":"Designing liposomal adjuvants for the next generation of vaccines","volume":"99","author":"Perrie","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7659","key":"10.1016\/j.jconrel.2022.11.053_bb0235","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922008070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922008070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:37:27Z","timestamp":1759163847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922008070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":47,"alternative-id":["S0168365922008070"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.053","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}